EI 201
Alternative Names: EI-201Latest Information Update: 16 Mar 2022
At a glance
- Originator eTheRNA Immunotherapies
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Anal cancer; Cervical cancer; Head and neck cancer; Penile cancer; Vulvovaginal cancer
Most Recent Events
- 09 Feb 2022 eTheRNA immunotherapies plans phase IIb/III trial in Solid tumors (eTheRNA immunotherapies pipeline, February 2021)
- 23 Dec 2021 Phase-I/II clinical trials in Anal cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in Belgium (IV) (EudraCT2021-004277-31)
- 23 Dec 2021 Phase-I/II clinical trials in Cervical cancer (Second-line therapy or greater, Recurrent, Metastatic disease) in Belgium (IV) (EudraCT2021-004277-31)